CQDM Quantum Leap Program

Insider Tip

Read the amount field carefully before you invest time: CQDM's own program-overview table says that for Quantum Leap it 'acts as a facilitator and provides guidance in structuring the financial package, without any guaranteed direct funding.' This is a matchmaking program, not a grant — the money comes from pharmaceutical members who choose to back your project, plus counterpart funding you secure. That changes how you should approach it. The first move is a conversation with Simon Fournier or Jesse Paterson about whether your technology maps onto member priorities; everything else follows from that answer. If you want a CQDM cheque with a published ceiling, its sibling SynergiQc program grants up to $1.5M over three years — but SynergiQc requires a Quebec public research institution as the applicant and a Quebec business partner, whereas Quantum Leap accepts one Canadian business on its own.

Rejection Pitfalls 5

• No alignment with the R&D priorities of CQDM's pharmaceutical members — this is the program's organising principle, not a scoring nicety
• No counterpart funding secured or credibly identified; partners fund only a portion
• Unclear or encumbered intellectual property, or no rights to the pre-existing IP the technology depends on

Success Profile

A Canadian SME or public research group with a drug-discovery technology — a platform, tool or method — that a large pharmaceutical company would plausibly adopt downstream, a clean IP position, a credible three-year plan, and either existing co-funding or a realistic path to it. The founders or PIs who do best here start with a conversation about member priorities rather than a finished proposal.

Evaluation Criteria

CQDM does not publish a scored rubric for Quantum Leap. What it does state is the basis of selection: identifying promising innovations and facilitating strategic collaborations aligned with the R&D priorities of CQDM's pharmaceutical members, and enabling projects with strong industry relevance and potential for downstream adoption. The application form makes the practical criteria visible — clear, transferable deliverables for use in biopharmaceutical research; the qualifications and complementarity of the team; a non-confidential scientific summary covering rationale, current state of advancement, preliminary data, objectives and milestones; a clean intellectual-property position; and a concrete proposal for what rights participating pharmaceutical members would receive in exchange for funding.

Application Steps

Required Documents 8

Eligible Expenses 1

• Expenses incurred by the business and/or the public research centre participating in the project — the only expense rule CQDM publishes for Quantum Leap

Intake Periods

CQDM's program-overview table gives Quantum Leap a predicted proposal-submission frequency of every three months. The program page states 'Next deadline: August 20' but does not name a year. Because the process is contact-first, the practical starting point is a conversation with CQDM rather than a submission window.

Deadline Notes

CQDM's English and French program pages both state 'Next deadline: August 20' without naming a year, and CQDM's program-overview table puts Quantum Leap's predicted frequency of proposal submissions at every three months. Do not plan against that date without confirming the current cycle with CQDM — and in any case the process starts with a conversation, not a submission: the application form itself instructs applicants to contact CQDM staff before submitting a project.

Ineligible Organizations

• Applicants outside Canada — the program is open to Canadian SMEs and public research institutions
• Projects with no drug-discovery technology component
• Projects that do not align with the R&D priorities of CQDM's pharmaceutical members

Stacking partner data not yet available.

Clawback Risk

Not-applicable Risk

CQDM provides no guaranteed direct funding for this program, so there is nothing for CQDM to claw back. Any repayment or performance condition would sit in the research agreement negotiated with the participating pharmaceutical partners and co-funders, which CQDM does not publish.